Novo Nordisk: diabetes drug reduces cardiovascular risk

(CercleFinance.com) - Novo Nordisk's Ozempic consistently reduced the risk of cardiovascular events in people with type-2 diabetes, post-hoc analyses showed.


Findings from several phase 3 trials presented at the European Society of Cardiology congress in Munich found that Ozempic reduced the risk of non-fatal heart attack, non-fatal stroke or cardiovascular death, the Danish drugmaker said.

Cardiovascular disease remains the leading cause of disability and death in people with type-2 diabetes, Novo said.

Ozempic was approved by the US Food and Drug Administration in December 2017, followed by the European Commission in February 2018.

Copyright (c) 2018 CercleFinance.com. All rights reserved.